Molecure S.A. Cash Flow Conversion Efficiency
Molecure S.A. cash flow conversion efficiency. Based on the latest financial reports, Molecure S.A. (MOC) has a cash flow conversion efficiency ratio of 0.266x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł26.15 Million ≈ $7.20 Million USD) by net assets (zł98.21 Million ≈ $27.03 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Molecure S.A. (2015–2024)
Cash flow conversion efficiency of Molecure S.A. from 2015 to 2024. This chart illustrates how Molecure S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Molecure S.A. share price for real-time trading data and today's change.
Molecure S.A. Cash Flow Conversion Ratio Explained
Molecure S.A. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Molecure S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Molecure S.A. ranked by their cash flow conversion efficiency. Also see MOC market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Sanmao Enterprise Group Co Ltd B
SHG:900922
|
0.100x |
|
Scanwolf Corporation Bhd
KLSE:7239
|
0.630x |
|
Cayman Tung Ling Co Ltd
TWO:2924
|
-0.055x |
|
Apollomics Inc. Class A Ordinary Shares
NASDAQ:APLM
|
4.001x |
|
Columbus Acquisition Corp Unit
NASDAQ:COLAU
|
-0.002x |
|
Next Science Ltd
AU:NXS
|
2.498x |
|
CZR Resources Ltd
AU:CZR
|
-0.033x |
|
Yellow Balloon Tour Co. Ltd
KQ:104620
|
-0.237x |
Annual Cash Flow Conversion Efficiency for Molecure S.A. (2015–2024)
The table below shows the annual cash flow conversion efficiency of Molecure S.A. from 2015 to 2024. Review MOC free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | zł103.41 Million ≈ $28.46 Million |
zł-56.99 Million ≈ $-15.68 Million |
-0.551x | -138.84% |
| 2023-12-31 | zł100.93 Million ≈ $27.78 Million |
zł-23.29 Million ≈ $-6.41 Million |
-0.231x | -185.69% |
| 2022-12-31 | zł126.45 Million ≈ $34.80 Million |
zł-10.21 Million ≈ $-2.81 Million |
-0.081x | +15.53% |
| 2021-12-31 | zł141.14 Million ≈ $38.84 Million |
zł-13.50 Million ≈ $-3.71 Million |
-0.096x | -123.87% |
| 2020-12-31 | zł143.40 Million ≈ $39.47 Million |
zł57.44 Million ≈ $15.81 Million |
0.401x | +545.88% |
| 2019-12-31 | zł79.13 Million ≈ $21.78 Million |
zł-7.11 Million ≈ $-1.96 Million |
-0.090x | -50.45% |
| 2018-12-31 | zł81.89 Million ≈ $22.54 Million |
zł-4.89 Million ≈ $-1.35 Million |
-0.060x | -195.95% |
| 2017-12-31 | zł29.72 Million ≈ $8.18 Million |
zł-599.63K ≈ $-165.03K |
-0.020x | +81.79% |
| 2016-12-31 | zł13.01 Million ≈ $3.58 Million |
zł-1.44 Million ≈ $-396.50K |
-0.111x | -11.67% |
| 2015-12-31 | zł15.43 Million ≈ $4.25 Million |
zł-1.53 Million ≈ $-421.14K |
-0.099x | -- |
About Molecure S.A.
Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed Phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis a… Read more